Loading…
Reported covered position: Deputy Chief Counsel, O&I, House Judiciary Com
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · third_quarter · Q3
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Source: Senate LDA
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Prescription Drug Labeling Promotion Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Medicare Pharmacy Transparency and Fair Auditing Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Pharmacy Transparency and Fair Auditing Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Medication Therapy Management Benefits Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medication Therapy Management Benefits Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Regulatory implementation of various tax provisions in the health reform legislation
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office